Drug Trial Radar · NCT02533973
Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population
Last checked: Nov 19, 2026Latest source record: Feb 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
951
Actual
Start
Sep 2015
Primary completion
Mar 6, 2018
Study completion Mar 6, 2018
Sponsor
- Lead sponsor
- LEO PharmaIndustry
- Sponsor type
- Industry
- Collaborators
- Tigermed Consulting Co., Ltd
- First posted
- Aug 27, 2015
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase 4 trial comparing the safety and efficacy of treatment with Xamiol® gel (calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)) once daily (as required) with Daivonex® scalp solution (calcipotriol 50 mcg/g) twice daily (as required) in Chinese subjects with scalp psoriasis
Conditions
- Psoriasis Vulgaris
Interventions
Xamiol® gelDrug
Daivonex® scalp solutionDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- safety of Xamiol® gel (adverse events)Time frame: 28 Weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Affiliated hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.